As of this week, the project had sequenced 39,500 genomes and returned reports for about 3,000 rare disease families and more than 600 cancer patients.
Genome Medical will use the platform for ongoing examination of patients' genomic data to augment data analysis, annotation, and interpretation.
The companies aim to offer an end-to-end oncology genomic testing and clinical interpretation service for clinical laboratory customers.
The deal will join Fabric's genome annotation technology with Veritas' myGenome personal whole-genome sequencing service.
Congenica will use the proceeds to establish its presence in the US and China, where it will court not only clinical genetics labs, but specialists, academics, biotech, and pharma.